With a slashed valuation the newly listed biotech heads for phase 3.
ApexOnco Front Page
Recent articles
An actinium-based backup and Werner helicase inhibitor are notable absences.
After trimming its cell therapy pipeline last year, the group is now out entirely.
The Titan CD8-guiding technology seems to have spawned a new variant.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
A single-arm trial was enough for J&J’s Inlexzo nod.
ESMO and the Triple Meeting approach.
